Award information
2025 Winner
Picture shows, left to right;
Nina Hossain, awards presenter; Mike White, Head of Lifesciences, HSBC Innovation Banking (award sponsor); Iain McGill, Chief Executive Officer, Quell Therapeutics Limited (award winner); Luke Henry, Chief Business Officer, Quell Therapeutics Limited (award winner); Melody A. Carey, President & Chief Executive Officer, Rx Communications Group, LLC (Mainline sponsor); and Neil Shah, Executive Director, Content & Strategy, Edison Group (Mainline sponsor).
2025 Shortlist
- Apollo Therapeutics Limited
- Beacon Therapeutics Limited
- Bioptimus
- Myricx Bio
- Nuclera Ltd
- Purespring Therapeutics Limited
- Quell Therapeutics Limited
- Zelluna ASA
Criteria
The Emerging Star will be a private or young public mediscience company that has demonstrable credibility in terms of business model/strategy, management team and financing. The winner's focus on innovation will also be key, with its technology/IP capable of significant market impact or disruption.
The Emerging Star may not be able to demonstrate too much of a track record, but it will be judged against the demanding criteria that exist for its quoted company peers. The purpose of this award is to broaden knowledge, exchange ideas and help private businesses understand what could be required of them in the quoted company universe.